|Bid||4.3900 x N/A|
|Ask||4.4300 x N/A|
|Day's Range||4.3700 - 4.6500|
|52 Week Range||4.0000 - 14.1900|
|Beta (5Y Monthly)||2.44|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
OTTAWA, ON, Oct. 26, 2020 /CNW/ - The Correctional Investigator of Canada, Dr.
TORONTO, Sept. 30, 2020 /CNW/ - OTT Pay, a leading provider of payment solutions in Canada, is proud to announce that it secured its Payment Card Industry Data Security Standard (PCI DSS) compliance certification on July 31st, 2020.
InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that all subjects participating in its second Phase 1 clinical trial with INM-755 have completed treatment. INM-755 is being developed as a topical CBN-based cream to potentially treat Epidermolysis Bullosa ("EB") as well as potentially other dermatological diseases.